Oncternal Therapeutics Stock Performance
| ONCT Stock | USD 1.14 0.02 1.72% |
The company holds a Beta of -0.62, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Oncternal Therapeutics are expected to decrease at a much lower rate. During the bear market, Oncternal Therapeutics is likely to outperform the market. At this point, Oncternal Therapeutics has a negative expected return of -1.29%. Please make sure to check Oncternal Therapeutics' jensen alpha, as well as the relationship between the kurtosis and day typical price , to decide if Oncternal Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Oncternal Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:20 | Dividend Date 2019-06-10 | Last Split Date 2024-01-08 |
1 | Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives | 09/12/2024 |
2 | Oncternal Therapeutics Inc Q2 2024 Earnings Call Highlights Advancements in Clinical ... | 10/09/2024 |
3 | Oncternal Therapeutics Now Covered by StockNews.com | 11/12/2024 |
4 | Oncternal announces workforce reduction, executive changes | 11/15/2024 |
| Begin Period Cash Flow | 37.1 M |
Oncternal |
Oncternal Therapeutics Relative Risk vs. Return Landscape
If you would invest 440.00 in Oncternal Therapeutics on August 24, 2024 and sell it today you would lose (326.00) from holding Oncternal Therapeutics or give up 74.09% of portfolio value over 90 days. Oncternal Therapeutics is currently does not generate positive expected returns and assumes 11.3869% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Oncternal, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncternal Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncternal Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Oncternal Therapeutics, and traders can use it to determine the average amount a Oncternal Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1133
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ONCT |
Estimated Market Risk
| 11.39 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.29 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Oncternal Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncternal Therapeutics by adding Oncternal Therapeutics to a well-diversified portfolio.
Oncternal Therapeutics Fundamentals Growth
Oncternal Stock prices reflect investors' perceptions of the future prospects and financial health of Oncternal Therapeutics, and Oncternal Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncternal Stock performance.
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (17.57) % | ||||
| Current Valuation | (11.01 M) | ||||
| Shares Outstanding | 2.96 M | ||||
| Price To Earning | (37.77) X | ||||
| Price To Book | 0.37 X | ||||
| Price To Sales | 1.59 X | ||||
| Revenue | 785 K | ||||
| Gross Profit | (31.49 M) | ||||
| EBITDA | 2.23 M | ||||
| Net Income | (39.48 M) | ||||
| Cash And Equivalents | 78.9 M | ||||
| Cash Per Share | 1.48 X | ||||
| Total Debt | 318 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.78 X | ||||
| Book Value Per Share | 3.09 X | ||||
| Cash Flow From Operations | (32.16 M) | ||||
| Earnings Per Share | (11.69) X | ||||
| Market Capitalization | 3.43 M | ||||
| Total Asset | 36.73 M | ||||
| Retained Earnings | (197.78 M) | ||||
| Working Capital | 30.86 M | ||||
| Current Asset | 27.27 M | ||||
| Current Liabilities | 6.3 M | ||||
About Oncternal Therapeutics Performance
Assessing Oncternal Therapeutics' fundamental ratios provides investors with valuable insights into Oncternal Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Oncternal Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 241.53 | 253.61 | |
| Return On Tangible Assets | (1.07) | (1.13) | |
| Return On Capital Employed | (1.32) | (1.39) | |
| Return On Assets | (1.07) | (1.13) | |
| Return On Equity | (1.31) | (1.38) |
Things to note about Oncternal Therapeutics performance evaluation
Checking the ongoing alerts about Oncternal Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncternal Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncternal Therapeutics generated a negative expected return over the last 90 days | |
| Oncternal Therapeutics has high historical volatility and very poor performance | |
| Oncternal Therapeutics may become a speculative penny stock | |
| The company reported the previous year's revenue of 785 K. Net Loss for the year was (39.48 M) with loss before overhead, payroll, taxes, and interest of (31.49 M). | |
| Oncternal Therapeutics currently holds about 78.9 M in cash with (32.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Oncternal Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Oncternal announces workforce reduction, executive changes |
- Analyzing Oncternal Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncternal Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Oncternal Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncternal Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncternal Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncternal Therapeutics' stock. These opinions can provide insight into Oncternal Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.